The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
Open accessAbstract
Our understanding of pathways leading to antitumor immunity may depend on an undistorted knowledge of the primary antigenic targets of patients' autologous T cell responses. In the melanoma model derived from patient DT, we applied cryopreserved short-term autologous mixed lymphocyte–tumor cell cultures (MLTCs) in combination with an IFN-γ enzyme-linked immunospot (ELISPOT) assay to cDNA expression screening. We identified three previously unknown peptides processed from melanosomal proteins tyrosinase (presented by HLA-A*2601 and -B*3801) and gp100 (presented by HLA-B*07021) and five neoantigens generated by somatic point mutations in the patient's melanoma. The mutations were found in the genes SIRT2, GPNMB, SNRP116, SNRPD1, and RBAF600. Peptides containing the mutated residues were presented by HLA-A*03011, -B*07021, and -B*3801. Mutation-induced functional impairment was so far demonstrated for SIRT2. Within MLTC responder populations that were independently expanded from the patient's peripheral blood lymphocytes of different years, T cells against mutated epitopes clearly predominated. These results document a high degree of individuality for the cellular antitumor response and support the need for individualizing the monitoring and therapeutic approaches to the primary targets of the autologous T cell response, which may finally lead to a more effective cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Jonuleit, H., Kühn, U., Müller, G., Steinbrink, K., Paragnik, L., Schmitt, E., Knop, J., & Enk, A. H. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271209 · Cited by 1,163
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Self-citationvan Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Brichard, V, Van Pel, A., Wölfel, T., Wölfel, C., De Plaen, E., Lethé, B., Coulie, P., & Boon, T. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.489 · Cited by 950
Self-citationGermline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818
Banchereau, J., Palucka, A. K., Dhodapkar, M. V., Burkeholder, S. B., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., et al. (2001) · PubMed · Cited by 806
Van den Eynde, B. J., & van der Bruggen, P. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80050-7 · Cited by 623
A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens
Rosenberg, S. A. (1999) · Immunity · doi:10.1016/s1074-7613(00)80028-x · Cited by 566
Belli, F., Testori, A., Rivoltini, L., Maio, M., Andreola, G., Sertoli, M. R., Gallino, G., Piris, A., Cattelan, A., Lazzari, I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.134 · Cited by 387
The Makings of a Tumor Rejection Antigen
Gilboa, E. (1999) · Immunity · doi:10.1016/s1074-7613(00)80101-6 · Cited by 381
Su, Z. Z., Dannull, J., Heiser, A., Yancey, D. R., Pruitt, S. K., Madden, J., Coleman, D., Niedzwiecki, D., Gilboa, E., & Vieweg, J. (2003) · PubMed · Cited by 366
Functional avidity maturation of CD8+ T cells without selection of higher affinity TCR
Slifka, M. K., & Whitton, J. L. (2001) · Nature Immunology · doi:10.1038/90650 · Cited by 344
Ennis, P. D., Zemmour, J., Salter, R. D., & Parham, P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2833 · Cited by 300
Mutation detection using Surveyor™ nuclease
Qiu, P., Shandilya, H., D'Alessio, J. M., O'Connor, K., Durocher, J., & Gerard, G. F. (2004) · BioTechniques · doi:10.2144/04364pf01 · Cited by 298
Coulie, P. G., Karanikas, V., Colau, D., Lurquin, C., Landry, C., Marchand, M., Dorval, T., Brichard, V., & Boon, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161260098 · Cited by 220
Wide spectrum of tumors in knock‐in mice carrying a Cdk4 protein insensitive to INK4 inhibitors
Sotillo, R., Dubus, P., Martn, J., de la Cueva, E., Ortega, S., Malumbres, M., & Barbacid, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6637 · Cited by 208
Derby, M. A., Alexander-Miller, M. A., Tse, R., & Berzofsky, J. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.1690 · Cited by 203
Immunity against cancer: lessons learned from melanoma
Houghton, A. N., Gold, J. S., & Blachere, N. E. (2001) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00195-3 · Cited by 190
O'Rourke, M. G. E., Johnson, M., Lanagan, C., See, J., Yang, J., Bell, J. R., Slater, G. J., Kerr, B. M., Crowe, B., Purdie, D. M., et al. (2003) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0375-x · Cited by 186
Perrod, S. (2001) · The EMBO Journal · doi:10.1093/emboj/20.1.197 · Cited by 165
Lonchay, C., van der Bruggen, P., Connerotte, T., Hanagiri, T., Coulie, P. G., Colau, D., Lucas, S., Pel, A. V., Thielemans, K., van Baren, N., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405743101 · Cited by 149
Immunotherapy: Bewitched, Bothered, and Bewildered No More
Steinman, R. M., & Mellman, I. (2004) · Science · doi:10.1126/science.1099688 · Cited by 136
Britten, C. M., Meyer, R. G., Kreer, T., Drexler, I., Wölfel, T., & Herr, W. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(01)00499-9 · Cited by 124
Self-citationKaranikas, V., Colau, D., Baurain, J., Chiari, R., Thonnard, J., Gutierrez-Roelens, I., Goffinet, C., SCHAFTINGEN, E. V., Weynants, P., Boon, T., et al. (2001) · PubMed · Cited by 119
Individually distinct transplantation antigens of chemically induced mouse tumors
Srivastava, P. K., & Old, L. J. (1988) · Immunology Today · doi:10.1016/0167-5699(88)91269-8 · Cited by 115
Kawakami, Y., Robbins, P. F., Wang, X., Tupesis, J. P., Parkhurst, M. R., Kang, X., Sakaguchi, K., Appella, E., & Rosenberg, S. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.12.6985 · Cited by 115
Zorn, E., & Hercend, T. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199902)29:02<592::aid-immu592>3.0.co;2-2 · Cited by 100
Anichini, A., Mortarini, R., Maccalli, C., Squarcina, P., Fleischhauer, K., Mascheroni, L., & Parmiani, G. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.1.208 · Cited by 91
Robbins, P. F., El‐Gamil, M., Li, Y. F., Zeng, G., Dudley, M. E., & Rosenberg, S. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.6036 · Cited by 86
Peggs, K. S., Verfuerth, S., Pizzey, A. R., Ainsworth, J., Moss, P. A. H., & Mackinnon, S. (2002) · Blood · doi:10.1182/blood.v99.1.213 · Cited by 68
Characterization of two Epstein‐Barr virus epitopes restricted by HLA‐B7
Hill, A. B., Worth, A. J. J., Elliott, T. J., Rowland‐Jones, S., Brooks, J. M., Rickinson, A. B., & McMichael, A. J. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250105 · Cited by 63
Lim, D., Bourcier, K., Freeman, G. J., & Hafler, D. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6214 · Cited by 62
Antitumor Immunity at Work in a Melanoma Patient
Coulie, P. G., Ikeda, H., Baurain, J., & Chiari, R. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60778-2 · Cited by 54
Regulating self-tolerance by deregulating gene expression
Gotter, J., & Kyewski, B. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.08.004 · Cited by 54
Point Mutation in Essential Genes with Loss or Mutation of the Second Allele
Beck‐Engeser, G., Monach, P. A., Mumberg, D., Yang, F. E., Wanderling, S. S., Schreiber, K., Espinosa, R., Beau, M. M. L., Meredith, S. C., & Schreiber, H. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.3.285 · Cited by 49
Yamshchikov, G. V., Thompson, L., Ross, W. G., et al. (2001) · PubMed · Cited by 42
Ma, L., Moan, J. E., Peng, Q., & Iani, V. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19981109)78:4<518::aid-ijc20>3.0.co;2-0 · Cited by 27
Cited by
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
CD8+ T cell differentiation and dysfunction in cancer
Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
Metadata
- Authors
- Lennerz, V., Fatho, M., Gentilini, C., Frye, R. A., Lifke, A., Ferel, D., Wölfel, C., Huber, C., & Wölfel, T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-10-24
- Volume
- 102
- Issue
- 44
- Pages
- 16013-16018
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1987288591
- Cited by
- 456
- References
- 38
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.